Insulin degludec
Journal of Mahatma Gandhi Institute of Medical Sciences · 2013
DOI: 10.4103/0971-9903.117795 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Mahatma Gandhi Institute of Medical Sciences, 2013. Verfasst von VishakhaV Jain und 1 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Insulin analogues have revolutionized the treatment of diabetes mellitus, and the advent of newer insulin analogues have provided better glycemic control with lesser incidence of hypoglycemia. Insulin degludec is a second-generation, ultra-long-acting acylated basal insulin analogue that possesses a flat, stable glucose-lowering effect in patients with type 1 or type 2 diabetes mellitus. Findings from clinical trials have demonstrated that new-generation, once-daily basal insulin degludec provides similar A1C control as compared to insulin glargine, both administered as basal-oral therapy or in combination with insulin aspart, with the added benefits of lower rates of hypoglycemia, particularly nocturnal hypoglycemia.
Zitieren
APA
Jain, V., & Gupta, O. (2013). Insulin degludec. Journal of Mahatma Gandhi Institute of Medical Sciences. https://doi.org/10.4103/0971-9903.117795
Vancouver
Jain V, Gupta O. Insulin degludec. Journal of Mahatma Gandhi Institute of Medical Sciences. 2013. doi:10.4103/0971-9903.117795
BibTeX
@article{Jain2013,
author = {Jain, VishakhaV and Gupta, Omprakash},
title = {Insulin degludec},
journal = {Journal of Mahatma Gandhi Institute of Medical Sciences},
year = {2013},
doi = {10.4103/0971-9903.117795}
}
EUVIMED